Literature DB >> 2546632

Human neutrophil-mediated lysis of ovarian cancer cells.

A Lichtenstein1, M Seelig, J Berek, J Zighelboim.   

Abstract

Because of recent questions concerning the sensitivity of human tumor cells to neutrophil-induced oxidative injury, we studied six freshly obtained human ovarian cancer (OC) specimens. Stimulation of neutrophils (PMNs) by phorbol myristate acetate (PMA) did not result in OC cytolysis during the first nine hours of incubation. However, three of six specimens were significantly lysed by stimulated PMNs when assay length was increased to 18 hours. Cytotoxicity was mediated by PMN production of reactive oxidative intermediates (ROIs). Presentation of ROIs to OC targets as preformed or enzymatically generated molecules in cell-free systems duplicated the enhanced lysis at 18 hours (as compared with six hours). Since addition of catalase at three or six hours did not inhibit enhanced lysis at 18 hours (achieved by PMNs or in cell-free systems), it appears that an initial ROI-mediated lethal event occurs early, but longer incubations are required for the event to become manifested as cell death. These data suggest that shorter assays may underestimate the potential of PMNs as effector cells against human tumor cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546632

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Neutrophil plasticity in the tumor microenvironment.

Authors:  Morgan A Giese; Laurel E Hind; Anna Huttenlocher
Journal:  Blood       Date:  2019-03-21       Impact factor: 22.113

2.  Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors.

Authors:  Edwin R Manuel; Jeremy Chen; Massimo D'Apuzzo; Melanie G Lampa; Teodora I Kaltcheva; Curtis B Thompson; Thomas Ludwig; Vincent Chung; Don J Diamond
Journal:  Cancer Immunol Res       Date:  2015-07-01       Impact factor: 11.151

3.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.

Authors:  Céline A Blache; Edwin R Manuel; Teodora I Kaltcheva; Andrea N Wong; Joshua D I Ellenhorn; Bruce R Blazar; Don J Diamond
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

4.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Role of oxygen intermediates in cytotoxicity: studies in chronic granulomatous disease.

Authors:  R L Roberts; B J Ank; M W Fanger; L Shen; E R Stiehm
Journal:  Inflammation       Date:  1993-02       Impact factor: 4.092

6.  Hepatocyte injury by activated neutrophils in vitro is mediated by proteases.

Authors:  B G Harbrecht; T R Billiar; R D Curran; J Stadler; R L Simmons
Journal:  Ann Surg       Date:  1993-08       Impact factor: 12.969

7.  The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice.

Authors:  W Walker; G Gallagher
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

8.  The interaction of HspA1A with TLR2 and TLR4 in the response of neutrophils induced by ovarian cancer cells in vitro.

Authors:  Magdalena Klink; Marek Nowak; Michał Kielbik; Katarzyna Bednarska; Edyta Blus; Marian Szpakowski; Krzysztof Szyllo; Zofia Sulowska
Journal:  Cell Stress Chaperones       Date:  2012-04-24       Impact factor: 3.667

9.  Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.

Authors:  S T Malik; D Martin; I Hart; F Balkwill
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

10.  Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment.

Authors:  Antonio Brú; Juan-Carlos Souto; Sonia Alcolea; Rosa Antón; Angel Remacha; Mercedes Camacho; Marta Soler; Isabel Brú; Amelia Porres; Luis Vila
Journal:  Mediators Inflamm       Date:  2010-02-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.